



## Enantioselective Synthesis of (-)-Indolizidine 239AB [(3R,5S,8aR)-3-Butyl-5-(3-hydroxypropyl)-octahydroindolizine]

Giang Vo Thanh, Jean-Pierre Célérier, and Gérard Lhommet\*


Université Pierre et Marie Curie, Laboratoire de Chimie des Hétérocycles URA 408. 4, Place Jussieu, 75252 Paris cedex 05, France

**Abstract** : A highly enantioselective synthesis of the indolizidine alkaloid **239AB** is described via the diastereoselective reduction of a chiral cyclic  $\beta$ -enamino ester prepared from (S)-pyroglutamic acid.


Copyright © 1996 Elsevier Science Ltd

Poison-frogs of the Dendrobatidae family have been a source of numerous alkaloids which present a significant neuromuscular activity.<sup>1</sup> Among the bicyclic skeleta, 3,5-disubstituted indolizidines **1** occur in a limited number of alkaloids of this class. Substituents are generally 3- and 5-alkyl chains<sup>2</sup> but the 5-hydroxypropyl group was characterized in indolizidine **239AB**<sup>2,3</sup> **1** ( $R^1=(CH_2)_3-OH$ ;  $R^2=nBu$ ). No racemic and only one asymmetric synthesis of this compound has been reported in the literature by Kibayashi *et al.* using a chiral diepoxide as asymmetric synthon.<sup>4</sup> As a part of an investigation into the reactivity of chiral cyclic  $\beta$ -enamino esters, we have been engaged in the synthesis of *cis* or *trans*<sup>5</sup> 3,5-disubstituted indolizidines bearing alkyl substituents.

In this paper we describe a general and highly enantioselective synthesis of the indolizidine **239AB** from a common chiral synthon. The key step of this synthesis depends, as shown in the disconnective analysis, on the diastereoselective reduction of the  $\beta$ -enamino ester **3** enantioselectively prepared in few steps from (S)-pyroglutamic acid **4** and which permits a *trans* disubstituted pyrrolidine to be obtained.



We had previously shown that *cis* disubstituted pyrrolidines could be prepared by catalytic hydrogenation of cyclic  $\beta$ -enamino esters<sup>5</sup> but no useful diastereoselection was observed when using chemical reducing agents to prepare *trans* compounds.<sup>6</sup> We have recently described new reduction conditions using sodium polyacetoxyborohydride which lead to *trans* disubstituted pyrrolidines with good diastereomeric excesses.<sup>7</sup> This synthetic pathway involves interaction between a hydroxy function and the reducing agent. So we decided to prepare a hydroxymethyl- $\beta$ -enamino ester and to perform a diastereoselective reduction of this compound.




**Reaction conditions** : i) 1°)  $(CH_3)_2SO_4$ , 2°)  $K_2CO_3$ ; ii) Meldrum's acid,  $Ni(acac)_2$ ,  $CHCl_3$ ,  $\Delta$ ; iii)  $MeONa/MeOH$ ,  $\Delta$ ; iv)  $NaBH_4$ ,  $AcOH$ ,  $CH_3CN$ ,  $0^\circ C$ ; v) diastereoselective carbamation; vi)  $TsCl$ ,  $(Et)_3N$ ; vii)  $Pr_2CuLi$ ,  $Et_2O$ ,  $-80^\circ C$ ; viii) DIBALH, toluene,  $-78^\circ C$ .

$\beta$ -Enamino ester **3** was enantioselectively prepared in six steps from (S)-pyroglutamic acid **4** in 42% overall yield. Reduction of **3** with  $NaBH_4/AcOH$  in acetonitrile lead to a mixture of *trans* and *cis*  $\beta$ -amino esters **5a** with a good d.e. (80%).<sup>7</sup> After separation by kinetically controlled carbamation of the *trans* derivative<sup>8</sup> and

activation of the alcohol function, the tosylate **5c** was transformed into 5-alkylated  $\beta$ -amino ester **5d**. The DIBAH reduction of **5d** finally led directly to the *N*-protected aldehyde **6** in 70% yield<sup>9</sup>.

Introduction of the hydroxypropyl substituent was achieved by Wittig condensation of **6** with a stabilized ylid **7** prepared in two steps from protected 2-bromoethanol<sup>10</sup>, and condensation with lithiotriphenylphosphinoacetone<sup>11</sup> with a 85% overall yield. Aminoenone **8** was obtained in 76% yield and then catalytically reduced to form the amino ketone **9**.



*Reaction conditions* : i) PPTs, 20°C; ii) BuLi, THF, Ph<sub>3</sub>P=CH-CO-CH<sub>3</sub>; iii) toluene, 80°C; iv) H<sub>2</sub>, PtO<sub>2</sub>, MeOH; v) 1°) H<sub>2</sub>, Pd/C, MeOH, 2°) HCl 0.5M/CH<sub>2</sub>Cl<sub>2</sub> 2.5/1, 20°C.

Hydrogenation of aminoketone **9** using H<sub>2</sub>/Pd-C led in one step and with a very high diastereoselectivity (d.e.=95%) to the enantiopure indolizidine **239AB** after final acidic hydrolysis to remove the protecting group.

In conclusion we report herein a highly enantioselective synthesis of natural indolizidine **239AB** in 15 steps and in a 5.6% overall yield. The strategy is sufficiently versatile to merit investigation of its generality in the synthesis of all natural hydroxyalkyl indolizidines.

**Acknowledgment:** We are grateful to U.C.I.B. (Usines Chimiques d'Ivry-la-Bataille, France) for the generous gift of (S)-pyroglutamic acid.

#### References

- Daly, J.W.; Spande, T.F. In *Alkaloids; Chemical and Biological Perspectives*; Pelletier, S.W.; Ed.; Wiley-Interscience: New York, 1986; Vol. 4, Chapter 1.
- Tokuyama, T.; Nishimoro, N.; Karle, I.L.; Edwards, M.W.; Daly, S.W. *Tetrahedron* **1986**, *42*, 3453.
- Daly, S.W.; Spande, T.F.; Whittaker, N.; Hight, R.J.; Feigl, D.; Nishimori, N.; Tokuyama, T.; Myers, C.W. *J. Nat. Prod.* **1986**, *49*, 265.
- Machinaga, N.; Kobayashi, C. *J. Org. Chem.* **1992**, *57*, 5178.
- Saliou, C.; Fleurant, A.; Célérier, J.P.; Lhommet, G. *Tetrahedron Lett.* **1991**, *28*, 3365.
- Fleurant, A.; Célérier, J.P.; Lhommet, G. *Tetrahedron: Asymmetry* **1993**, *4*, 1429.
- Vo Thanh, G.; Célérier, J.P.; Fleurant, A.; Grandjean, C.; Rosset, S.; Lhommet, G. *Heterocycles* **1996**, *8*, in press.
- Fleurant, A.; Grandjean, C.; Provot, O.; Rosset, S.; Célérier, J.P.; Lhommet, G. *Heterocycles* **1993**, *5*, 929.
- Luly, J.R.; Dellaria, J.F.; Plattner, J.F.; Soderquist, J.L.; Yi, N. *J. Org. Chem.* **1987**, *52*, 1487.
- Meyers, A.I.; Comins, D.L.; Roland, D.M.; Henning, R.; Shimizu, K. *J. Am. Chem. Soc.* **1979**, *101*, 7104.
- Cooke Jr., M.P. *J. Org. Chem.* **1973**, *38*, 4082.
- Satisfactory analytical and spectral data were obtained for (-) (3R,5S, 8aR)-3-butyl-5-(3-hydroxypropyl) octahydroindolizine **1**. [ $\alpha$ ]<sub>D</sub><sup>21</sup> -96 (c=0.14, MeOH). *Anal.* Calcd. for C<sub>13</sub>H<sub>29</sub>NO: C, 75.26; H, 12.21; N, 5.85. Found: C, 75.02; H, 12.33; N, 5.97. IR (neat)  $\nu$  (cm<sup>-1</sup>)= 3360; 2940; 2860; 2820; 1450. <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm)= 0.86 (t, 3H, J=7Hz); 0.95-1.98 (m, 20H); 2.30-2.45 (m, 1H); 2.50-2.60 (m, 1H); 3.20-3.30 (m, 1H); 3.35-3.50 (m, 1H); 3.55-3.65 (m, 1H); 4.80-5.20 (br.s, 1H). <sup>13</sup>C NMR (64.25 MHz, CDCl<sub>3</sub>)  $\delta$  (ppm)=14.2, 23.0, 24.4, 25.0, 26.1, 28.0, 29.0, 29.2, 29.8, 30.8, 31.5, 55.2, 58.7, 59.3, 63.3.